TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Core Insights - TG Therapeutics published two journal articles discussing the evolution of CD20 treatments for multiple sclerosis (MS) and the experiences of seven patients who switched to BRIUMVI® (ublituximab-xiiy) from other anti-CD20 therapies due to efficacy or tolerability concerns [1][2][5] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, including BRIUMVI for relapsing forms of multiple sclerosis (RMS) [24][25] - BRIUMVI has received FDA approval for treating adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [24][6] Clinical Trials - The ULTIMATE I & II trials are randomized, double-blind, controlled studies assessing BRIUMVI in patients with RMS over 96 weeks, enrolling a total of 1,094 patients across 10 countries [3] - Patients in these trials were required to have experienced at least one relapse in the previous year or have specific MRI findings, with an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline [3] Treatment Insights - BRIUMVI is a monoclonal antibody targeting a unique epitope on CD20-expressing B-cells, designed to enhance B-cell depletion at lower doses through glycoengineering [4] - The retrospective case series published in Frontiers in Immunology highlights the clinical outcomes of seven MS patients who switched to ublituximab, emphasizing the importance of therapeutic efficacy and tolerability in treatment decisions [5] Market Context - The prevalence of MS is significant, with nearly 1 million people living with MS in the United States, and approximately 85% initially diagnosed with relapsing-remitting MS [23] - The global MS population exceeds 2.3 million, indicating a substantial market for effective treatments like BRIUMVI [23]